Genea, Novogen deal

Novogen partnered with Genea's Genea Biocells Pty. Ltd. subsidiary to conduct preclinical testing of super-benzopyrans to treat degenerative diseases of the nervous system and muscles, including infantile neuraxonal dystrophy, fascioscapularhumeral dystrophy, amyotrophic lateral sclerosis (ALS), Sanfillipo syndrome and Alzheimer's disease (AD). Genea and Novogen said preliminary research conducted by both companies showed that super-benzopyrans appear to be effective at promoting the "normalization" of stem cells associated with some forms of neurodegeneration and muscular dystrophy. The companies are sharing R&D costs. Genea said Novogen will conduct all clinical development of drug candidates. ...